Biropepimut
Vaccineexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 30, 2017 (NCT02873819)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Melanoma-associated antigen 3Immunity, active
MAGEA3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gl-0817
- gl-0817
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02873819 | Phase 2 | Mar 30, 2017 | Gliknik Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gliknik Inc. | For profit | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1